Relationship between Bone Mineral Density and Serum Osteoprotegerin in Patients with Chronic Heart Failure

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Chen, Ying Hsien ^a,b   Wu, Yen Wen ^a,b,c   Yang, Wei Shiung ^a,b   Wang, Shoei Shen ^a,b   Lee, Chi Ming ^a,b   Chou, Nai Kuan ^a,b   Hsu, Ron Bin ^a,b   Lin, Yen Hung ^a,b   Lin, Mao Shin ^a,b   Ho, Yi Lwun ^a,b   Chen, Ming Fong ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; FOLLISTATIN; MYOSTATIN; OSTEOPROTEGERIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BONE DENSITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE REGISTRY; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GENDER; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HIP; HUMAN; HUMAN TISSUE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RISK ASSESSMENT;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; BIOLOGICAL MARKERS; BONE DENSITY; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; FEMUR; HEART FAILURE; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; OSTEOPROTEGERIN;

EID: 84865608507     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044242     Document Type: Article

References (33)

1. Abou-Raya S, Abou-Raya A, (2009) Osteoporosis and congestive heart failure (CHF) in the elderly patient: double disease burden. Arch Gerontol Geriatr 49: 250-254.
2. van Diepen S, Majumdar SR, Bakal JA, McAlister FA, Ezekowitz JA, (2008) Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16,294 patients. Circulation 118: 1946-1952.
3. Carbone L, Buzkova P, Fink HA, Lee JS, Chen Z, et al. (2010) Hip fractures and heart failure: findings from the Cardiovascular Health Study. Eur Heart J 31: 77-84.
4. Shane E, Mancini D, Aaronson K, Silverberg SJ, Seibel MJ, et al. (1997) Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 103: 197-207.
5. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, et al. (2004) Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol 287: H2023-2026.
6. Barasch E, Gottdiener JS, Aurigemma G, Kitzman DW, Han J, et al. (2009) Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study. Circ Heart Fail 2: 303-310.
7. Lim LS, Fink HA, Kuskowski MA, Taylor BC, Schousboe JT, et al. (2008) Loop diuretic use and increased rates of hip bone loss in older men: the Osteoporotic Fractures in Men Study. Arch Intern Med 168: 735-740.
8. Loncar G, Fulster S, von Haehling S, Popovic V (2011) Metabolism and the heart: An overview of muscle, fat, and bone metabolism in heart failure. Int J Cardiol.
9. Bozic B, Loncar G, Prodanovic N, Radojicic Z, Cvorovic V, et al. (2010) Relationship between high circulating adiponectin with bone mineral density and bone metabolism in elderly males with chronic heart failure. J Card Fail 16: 301-307.
10. Ueland T, Dahl CP, Kjekshus J, Hulthe J, Bohm M, et al. (2011) Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail 4: 145-152.
11. Loncar G, Bozic B, Cvorovic V, Radojicic Z, Dimkovic S, et al. (2010) Relationship between RANKL and neuroendocrine activation in elderly males with heart failure. Endocrine 37: 148-156.
12. Huang KC, Cheng WC, Yen RF, Tsai KS, Tai TY, et al. (2004) Lack of independent relationship between plasma adiponectin, leptin levels and bone density in nondiabetic female adolescents. Clin Endocrinol (Oxf) 61: 204-208.
13. Hwang JJ, Yang WS, Chiang FT, Chen MF, Lin HJ, et al. (2009) Association of circulating matrix metalloproteinase-1, but not adiponectin, with advanced coronary artery disease. Atherosclerosis 204: 293-297.
14. Witasp A, Carrero JJ, Hammarqvist F, Qureshi AR, Heimburger O, et al. (2011) Expression of osteoprotegerin in human fat tissue; implications for chronic kidney disease. Eur J Clin Invest 41: 498-506.
15. Boyle WJ, Simonet WS, Lacey DL, (2003) Osteoclast differentiation and activation. Nature 423: 337-342.
16. Baldini V, Mastropasqua M, Francucci CM, D'Erasmo E, (2005) Cardiovascular disease and osteoporosis. J Endocrinol Invest 28: 69-72.
17. Daniels LB, Maisel AS, (2007) Natriuretic peptides. J Am Coll Cardiol 50: 2357-2368.
18. Kochetkova EA, Nevzorova VA, Maistrovskaia Iu V, Massard G, (2010) [Osteoprotegerin and bone mineral density in patients with chronic obstructive pulmonary disease]. Ter Arkh 82: 10-14.
19. Pobeha P, Ukropec J, Skyba P, Ukropcova B, Joppa P, et al. (2011) Relationship between osteoporosis and adipose tissue leptin and osteoprotegerin in patients with chronic obstructive pulmonary disease. Bone 48: 1008-1014.
20. Jabbar S, Drury J, Fordham JN, Datta HK, Francis RM, et al. (2011) Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis. J Clin Pathol.
21. Jankowska EA, Jakubaszko J, Cwynar A, Majda J, Ponikowska B, et al. (2009) Bone mineral status and bone loss over time in men with chronic systolic heart failure and their clinical and hormonal determinants. Eur J Heart Fail 11: 28-38.
22. Zittermann A, Schleithoff SS, Koerfer R, (2006) Markers of bone metabolism in congestive heart failure. Clin Chim Acta 366: 27-36.
23. Lee AH, Mull RL, Keenan GF, Callegari PE, Dalinka MK, et al. (1994) Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med 96: 35-41.
24. Lyons K, Majumdar SR, Ezekowitz JA (2011) The Unrecognized Burden of Osteoporosis-Related Vertebral Fractures in Patients with Heart Failure. Circ Heart Fail.
25. Gruson D, Ahn SA, Ketelslegers JM, Rousseau MF, (2011) Increased plasma myostatin in heart failure. Eur J Heart Fail 13: 734-736.
26. Zamora E, Simo R, Lupon J, Galan A, Urrutia A, et al. (2010) Serum myostatin levels in chronic heart failure. Rev Esp Cardiol 63: 992-996.
27. Lee SJ, (2004) Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 20: 61-86.
28. Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, et al. (2003) Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 361: 1077-1083.
29. Herndon DN, Hart DW, Wolf SE, Chinkes DL, Wolfe RR, (2001) Reversal of catabolism by beta-blockade after severe burns. N Engl J Med 345: 1223-1229.
30. Jono S, Otsuki S, Higashikuni Y, Shioi A, Mori K, et al. (2010) Serum osteoprotegerin levels and long-term prognosis in subjects with stable coronary artery disease. J Thromb Haemost 8: 1170-1175.
31. Shaker OG, El-Shehaby A, Nabih M, (2010) Possible role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as markers of plaque instability in coronary artery disease. Angiology 61: 756-762.
32. Roysland R, Masson S, Omland T, Milani V, Bjerre M, et al. (2010) Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial. Am Heart J 160: 286-293.
33. Ueland T, Yndestad A, Oie E, Florholmen G, Halvorsen B, et al. (2005) Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 111: 2461-2468.